NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Stock Information for NervGen Pharma Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NervGen Pharma Corp.

NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Canadian Investment Regulatory Organization Trade Resumption - NGEN
Canadian Investment Regulatory Organization Trading Halt - NGEN
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
Canadian Investment Regulatory Organization Trade Resumption - NGEN
Canadian Investment Regulatory Organization Trading Halt - NGEN
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
NervGen Pharma Grants Stock Options

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.